A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma.
Francis Ayuk,Avichai Shimoni,Arnon Nagler,Rainer Schwerdtfeger,Michael G. Kiehl,Herbert G. Sayer,Tatjana Zabelina,Axel R. Zander,N Kröger +8 more
TL;DR: Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma is studied.
Journal ArticleDOI
Anti-T Lymphocyte Globulin (ATG) Induces Generation of Regulatory T Cells, at Least Part of Them Express Activated CD44
Orly Shimony,Arnon Nagler,Yechiel N. Gellman,Efrat Refaeli,Nir Rosenblum,Lora Eshkar-Sebban,Ronit Yerushalmi,Avichai Shimoni,Simon D. Lytton,Anfisa Stanevsky,Reuven Or,David Naor +11 more
TL;DR: It is shown that the anti-T lymphocyte immunoglobulin (ATG) can induce Treg cells following 24-h incubation in human peripheral blood mononuclear cells (PBMCs) and that these cells retain their suppressor function after freezing and thawing or irradiation.
Journal ArticleDOI
Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia
Yogesh Jethava,Simona Sica,Bipin N. Savani,F Socola,Madan Jagasia,M. Mohty,Arnon Nagler,Andrea Bacigalupo +7 more
TL;DR: Refinement of standard regimens has led to a reduction of non-relapse mortality, also in the older age group over 60 or 70 years of age, especially for patients who undergo transplant with residual or refractory disease.
Journal ArticleDOI
The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma
Abraham Avigdor,Tsvi Sirotkin,Meirav Kedmi,Elena Ribakovsy,Miriam Berkowicz,Yaron Davidovitz,Abraham Kneller,Drorit Merkel,Yulia Volchek,Tima Davidson,Elinor Goshen,Sara Apter,Avichai Shimoni,Isaac Ben-Bassat,Arnon Nagler +14 more
TL;DR: This retrospective analysis demonstrates that the superiority of VACOP-B over CHOP21 for treatment of PMBCL disappeared once rituximab was added, and the potential benefit of using interim PET activity as a guide for continuing therapy in patients withPMBCL remains unclear.
Journal ArticleDOI
Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines.
TL;DR: Significant antitumor effects could again be documented following concomitant administration of allogeneic spleen cells and IL-2, and pilot clinical trials are currently underway, investigating the effect of cytokine-mediated immunotherapy (CMI) in MRD following conventional and high-dose cytoreductive anticancer therapy in conjunction with ABMT.